# (19) World Intellectual Property Organization

International Bureau



#### 

### (43) International Publication Date 21 July 2005 (21.07.2005)

**PCT** 

## (10) International Publication Number WO 2005/066160 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/506, A61P 33/06, C07F 7/08

C07D 405/04,

(21) International Application Number:

PCT/GB2005/050001

(22) International Filing Date: 6 January 2005 (06.01.2005)

(25) Filing Language:

**English** 

(26) Publication Language:

**English** 

(30) Priority Data: 0400290.3

8 January 2004 (08.01.2004) GB

(71) Applicant (for all designated States except US): MEDI-VIR AB [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GILBERT, Ian [GB/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). NGUYEN, Corinne [FR/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). RUDA, Gian Filippo [IT/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). SCHHIPANI, Alessandro [IT/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). KASINATHAN, Ganasan [MY/GB]; Welsh School of Pharmacy, Cardiff University, Cardiff, Gwent CF1 0XF (GB). JOHANSSON, Nils-Gunnar [SE/SE]; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE). PACANOWSKA, Dolores Gonzales [ES/ES]; Instituto de Parasitologia y Biomedicina, Consejo

Superior de Investigaciones Cientificas, C/Ventanilla 11, E-18001 Granada (ES).

- (74) Agents: TEUTEN, Andrew, J. et al.; Sagittarius Intellectual Property Consultants Ltd, Taylor House, 39 High Street, Marlow, Bucks SL7 1AF (GB).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DUTPASE INHIBITORS

$$\begin{array}{c} R6 \\ R7-E-C_0-C_3-alkylene-D-C_0-C_3-alkylene \\ R8 \end{array}$$

(57) Abstract: Deoxyuridine derivatives of Formula (I'); where A is O, S or CH<sub>2</sub>; B is O, S or CHR<sup>3</sup>; R<sup>1</sup> is H, or various substituents; R<sup>2</sup> is H, F; R<sup>3</sup> is H, F, OH, NH<sub>2</sub>; or R<sup>2</sup> and R<sup>3</sup> together form a chemical bond; D is -NHCO-, -CONH-, -0-, -C(=O)-, -CH=CH, -C=C-, -NR<sup>5</sup>-; R<sup>4</sup> is hydrogen or various substituents; R<sup>5</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkanoyl; E is Si or C; R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system have utility in the prophylaxis o treatment of parasitic diseases such as malaria.